AbbVie Inc. (4AB.DE) Stock Price

€195.1 0.6%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    5

  • Fundamental

    4

  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on AbbVie Inc., AI stock picks, stock alerts and much more.

Sign up

4AB.DE AI Stock Analysis

AI stock analysis for 4AB.DE is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like AbbVie Inc. (4AB.DE) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

AbbVie Inc. (4AB.DE) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of AbbVie Inc. (4AB.DE), currently trading at €195.1, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 4AB.DE

LSE

  • AbbVie Inc.

  • Symbol

    4AB.DE

  • Market

    XETRA

  • Industry

    Drug Manufacturers - General

  • Market Cap

    344.3B

Similar Stocks

PFE.F Pfizer Inc.
PFE.F		 €24.06
1%
3
AMG.DE Amgen Inc.
AMG.DE		 €289.7
0.2%
5
ZEG.DE AstraZeneca PLC
ZEG.DE		 €141.1
0.6%
5
PFE.DE Pfizer Inc.
PFE.DE		 €24.01
0.8%
4
IDP.DE Biogen Inc.
IDP.DE		 €131.7
1.6%
4

News

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
March 17, 2025. Biztoc.com
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025. GlobeNewswire
Bank of America Raises AbbVie (NYSE:ABBV) Price Target to $223.00

Bank of America Raises AbbVie (NYSE:ABBV) Price Target to $223.00
March 6, 2025. ETF Daily News
NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound
March 4, 2025. GlobeNewswire

4AB.DE Alternative Data

Web Traffic

AbbVie Inc. receives an estimated 1.3M monthly visitors to abbvie.com.

  • Web Traffic

    1280073

  • Change from Previous Month

    1.7%

  • 3 Month Change

    13.4%

  • YoY Change

    13.4%

News Mentions

AbbVie Inc. was mentioned 3 times in the news yesterday.

  • News Mentions

    3

  • Daily Change

    0%

  • 1 Month Change

    200%

  • 3 Month Change

    50%

Twitter Followers

AbbVie Inc. has 79,254 Twitter Followers on its main Twitter (also known as X) account, which is down by -0% over the last month.

  • Twitter Followers

    79254

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0.3%

TikTok Followers

AbbVie Inc. has 3,776 TikTok Followers on its main TikTok account, up by 0.7% over the last month.

  • TikTok Followers

    3776

  • Daily Change

    0.1%

  • 1 Month Change

    0.7%

  • 3 Month Change

    14%

Facebook Engagement

AbbVie Inc. has engaged 759 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    759

  • Daily Change

    2.4%

  • 1 Month Change

    256.3%

  • 3 Month Change

    66.2%

Instagram Followers

AbbVie Inc. has 40,559 Instagram Followers on its main Instagram account, up by 1.6% over the last month.

  • Instagram Followers

    40559

  • Daily Change

    0%

  • 1 Month Change

    1.6%

  • 3 Month Change

    3.8%

Youtube Subscribers

AbbVie Inc. has 6,900 subscribers on its main Youtube channel, up by 1.2% over the last month.

  • Youtube Subscribers

    6900

  • Daily Change

    0%

  • 1 Month Change

    1.2%

  • 3 Month Change

    4.5%

LinkedIn Followers

1,540,212 are following AbbVie Inc. on LinkedIn, up by 1.7% over the last month.

  • LinkedIn Followers

    1540212

  • Daily Change

    0.1%

  • 1 Month Change

    1.7%

  • 3 Month Change

    4.5%

Job Postings

AbbVie Inc. currenly has an estimated 1,000 open job postings.

  • Job Postings

    1000

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

AbbVie Inc. has been mentioned an estimated 2 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    2

  • Daily Change

    0%

LinkedIn Employees

According to LinkedIn, AbbVie Inc. has 51,755 employees, down by -4% over the last month.

  • LinkedIn Employees

    51755

  • Daily Change

    0.1%

  • 1 Month Change

    4%

  • 3 Month Change

    5%

App Downloads

  • App Downloads

    2

  • Daily Change

    0%

  • 1 Month Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at AbbVie Inc. is 78 out of 100 (bullish).

  • Business Outlook

    78

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

4AB.DE Financials

4AB.DE Key Metrics

  • Total Revenue

    $15.1B

  • Net Income

    -$22M

  • Earnings per Share

    -$0.0181

  • Free cash flow

    $6.8B

  • EBITDA

    $535M

  • EBITDA Ratio

    0.0354258

  • Total Assets

    $135.2B

4AB.DE 2-year Revenue & Income
4AB.DE 2-year Free Cash Flow

4AB.DE Technicals

4AB.DE SMA
4AB.DE RSI

FAQ

What's the current price of AbbVie Inc. (4AB.DE) Stock?
The price of an AbbVie Inc. (4AB.DE) share is €195.1.

What's the market cap of AbbVie Inc.?
The current market cap of AbbVie Inc. is 344.3B.

Should I buy or sell 4AB.DE?
AbbVie Inc. shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, AbbVie Inc. is better viewed as a hold or accumulate position while waiting for further developments.

Is AbbVie Inc. a good investment?
The current analysis of AbbVie Inc.'s fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in AbbVie Inc.'s portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy AbbVie Inc. (4AB.DE) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for AbbVie Inc. stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to AbbVie Inc. (4AB.DE) that investors often compare it to?
AbbVie Inc. (4AB.DE) is often compared to similar stocks such as Pfizer Inc., Amgen Inc., AstraZeneca PLC, Pfizer Inc. and Biogen Inc..

What is the forecast for AbbVie Inc.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast AbbVie Inc.'s stock price to be around €195.3 in 2026. Starting from the current price of €195.1, this represents a 0.1% change in price, indicating a neutral outlook for the stock.

How to buy AbbVie Inc. (4AB.DE) Stock?
AbbVie Inc. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy AbbVie Inc. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.